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San Paolo Hospital, University of Milan, Milan, ItalyAbstractMigrant and Italian HIV-infected patients (n = 5773) enrolled in the ICONA cohort in 2004–2014 were compared for disparities in access to
an initial antiretroviral regimen and/or risk of virologic failure (VF), and determinants of failure were evaluated. Variables associated with
initiating antiretroviral therapy (ART) were analysed. Primary endpoint was time to failure after at least 6 months of ART and was
defined as: VF, first of two consecutive virus loads (VL) >200 copies/mL; treatment discontinuation (TD) for any reason; and treatment
failure as confirmed VL >200 copies/mL or TD. A Poisson multivariable analysis was performed to control for confounders. Migrants
presented significantly lower CD4 counts and more frequent AIDS events at baseline. When adjusting for baseline confounders, migrants
presented a lower likelihood to begin ART (odds ratio 0.80, 95% confidence interval (CI) 0.67–0.95, p 0.012). After initiating ART, the
incidence VF rate was 6.4 per 100 person-years (95% CI 4.8–8.5) in migrants and 2.7 in natives (95% CI 2.2–3.3). Multivariable analysis
confirmed that migrants had a higher risk of VF (incidence rate ratio 1.90, 95% CI 1.25–2.91, p 0.003) and treatment failure (incidence
rate ratio 1.16, 95% CI 1.01–1.33, p 0.031), with no differences for TD. Among migrants, variables associated with VF were age,
unemployment and use of a boosted protease inhibitor–based regimen versus nonnucleoside reverse transcriptase inhibitors. Despite the
use of more potent and safer drugs in the last 10 years, and even in a universal health care setting, migrants living with HIV still present
barriers to initiating ART and an increased risk of VF compared to natives.
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p://dx.doi.org/10.1016/j.cmi.2015.10.026IntroductionMigrant populations in Europe are disproportionately affected by
HIV compared to natives; in fact, according to the European
Centre for Disease Prevention and Control, in the period
2007–2011, 39% of all new cases of HIV infection were regis-
tered in foreign patients [1], who represented only 9.7% of theious Diseases. Published by Elsevier Ltd. All rights reserved
CMI Saracino et al. Virologic failure in migrants 288.e2total resident population. In Italy, the proportion of nonnationals
among new HIV cases increased up to 24% in the last available
2013 report [2], with a median incidence of HIV infection of 19.1
in migrants compared to 4.9 per 100|000 in Italian-born subjects.
This situation reflects the arrival of migrants from countries with
generalized HIV epidemics; in addition, HIV sexual transmission
after arrival in Europe has also been described in some pop-
ulations with a high behavioural risk [3].
Reports from various European countries univocally indicate
that migrants have higher rates of late presentation compared
to natives [1,2,4–6], as was also confirmed in Italy by a recent
survey [7], suggesting that barriers still exist which hamper the
access to health services, thus delaying HIV testing, linkage to
care and antiretroviral therapy (ART) initiation [8,9]. This risk is
especially high for nonlegal immigrants [10,11].
Data regarding the probability of response to ART in migrant
patients are still scarce and, at least in part, controversial. In
fact, while some studies found a reduced virologic and/or
immunologic response in nonautochthonous patients compared
to natives [12–14], other surveys found no difference in terms
of therapy outcome and overall prognosis after adjusting for
baseline viroimmunologic parameters [15–19]. Nevertheless,
diversities in virus characteristics (HIV-1 subtype, coreceptor
tropism, rate of transmitted drug resistance) [20,21], host ge-
netic factors (such as frequency of human leukocyte antigen
(HLA) B5701 status) [22], prevalence of other concomitant
infections and comorbidities, different tolerability profiles and
side effects [23] might influence ART response in the immigrant
population.
The aims of this study were to evaluate possible disparities in
access and/or risk of failure to first ART regimens in migrants
compared to Italian-born patients enrolled in the ICONA
cohort and to assess determinants of failure for migrants living
with HIV.Patients and MethodsThe ICONA Foundation Study is an observational cohort of
HIV-infected individuals who are antiretroviral naïve at the time
of enrolment. This cohort was set up in January 1997 and
currently consists of more than 13|000 patients from 50 Italian
infectious disease units [24]. Demographic and socio-
behavioural data, initiation and discontinuation dates of each
antiretroviral drug, HIV virus load (VL) and CD4 cell count
every 4–6 months and AIDS-defining diseases according to US
the Centers for Disease Control and Prevention criteria are
recorded for all enrolled patients.
In the present study, all native and migrant naïve patients
enrolled in ICONA in the last 10 years, from January 2004 toClinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and InMarch 2014, were included. Migrants were defined as those
born outside Italy, based on their geographical origin, which
was derived from nationality or from country of birth or origin,
and classified as follows: Western countries (Europe, North
America, Australia, New Zealand), North Africa and the Middle
East, sub-Saharan Africa, Latin America and Asia.
Comparison between natives and migrants was performed
by the chi-square test for categorical variables and the
nonparametric Wilcoxon rank-sum test for continuous vari-
ables. Variables associated with ART initiation were evaluated.
A multivariable logistic model was performed to assess the
adjusted odds ratio (OR) and 95% confidence interval (95%
confidence interval (CI)) for beginning ART.
Further analysis was carried out to identify the impact of
migration status on response to therapy. The outcome vari-
ables were three different measures of response to ART: time
to virologic failure (VF) after at least 6 months of therapy,
defined as the first of two consecutive VL >200 copies/mL;
treatment discontinuation for any reason (TD); and treatment
failure (TF), defined as confirmed VL of >200 copies/mL or TD.
Different patient population were considered for analysing
the occurrence of the different outcomes: all subjects who
initiated ART and had available at least 2 HIV RNA assessments
6 months after start of therapy for time to VF; and all patients
initiating ART with at least one HIV RNA assessment during
therapy for evaluating TF and TD. Survival analysis was based on
the Kaplan-Meier method to estimate the cumulative proba-
bility of VF, TF and TD. A multivariable Poisson model was
performed to identify factors independently associated with the
three different outcomes.
At multivariable analysis, the main covariate of interest
(native/migrant) was adjusted for all factors retained from the
univariate analysis because of a p value of <0.10. Analyses were
performed by Stata 10 (StataCorp, College Station, TX, USA).ResultsBaseline characteristics
A total of 5773 HIV-positive, ART-naïve patients were enrolled
in the period 2004–2014, of whom 1175 were migrants
(20.4%). Migrants were mostly from sub-Saharan Africa (35.5%)
and Latin America (29.1%), followed by Western countries
(27.1%, with 10.9% of these from Eastern Europe), Asia (4.3%)
and North Africa and the Middle East (4%). Median duration of
residency in Italy was 5 years (interquartile range 1–10).
Baseline characteristics significantly differed between the
two groups (Table 1); in particular, lower CD4 counts and
higher frequency of AIDS events at enrolment were observed
in migrants versus natives.fectious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 22, 288.e1–288.e8
TABLE 1. Characteristics of migrants and natives at study
enrolment
Characteristic Migrants Natives p
Number 1175 (20.4%) 4598 (79.6%)
Male gender, n (%) 670 (57.0%) 3914 (85.1%) <0.001
Age, years, median (IQR) 34 (28–40) 39 (32–47) <0.001
Nationality, n (%)
Sub-Saharan Africa 416 (35.5%) —
Latin America 342 (29.1%) —




Asia 51 (4.3%) —
Years of residency in Italy,
median (IQR)
5 (1–10) —
Months from first HIV test
and first visit,
median (IQR)
1.2 (0.4–8.4) 2.2 (0.5–16.1) <0.001
Mode of HIV transmission,
n (%)
Heterosexual contact 702 (59.7%) 1634 (35.5%) <0.001
Homosexual contact 310 (26.4%) 2194 (47.7%)
Intravenous drug use 47 (4.0%) 436 (9.5%)
Other/unknown 116 (9.9%) 334 (7.3%)
Recent drug use at
enrolment, n (%)
No 900 (76.7%) 3352 (72.9%) 0.005
Yes 21 (1.7%) 149 (3.2%)
Unknown 254 (21.6%) 1097 (23.9%)
Smoking habit at
enrolment, n (%)
No 791 (67.3%) 2158 (46.9%) <0.001
Yes 281 (23.9%) 2009 (43.7%)
Unknown 103 (8.8%) 431 (9.4%)
Education, n (%)
Elementary school 160 (13.6%) 172 (3.7%) <0.001
Junior high school 195 (16.6%) 903 (19.6%)
High school 221 (18.8%) 1414 (30.8%)
University 87 (7.4%) 566 (12.3%)
Missing data 512 (43.6%) 1543 (33.6%)
Occupation, n (%)
Full-time worker 350 (29.9%) 2085 (45.3%) <0.001
Housewife 47 (4.0%) 109 (2.4%)
Self-employed 93 (7.9%) 701 (15.2%)
Temporary employed 99 (8.4%) 78 (1.7%)
Retired 2 (0.2%) 167 (3.6%)
Student 24 (2.0%) 183 (4.0%)
Unemployed 306 (26.0%) 445 (9.7%)
Other/missing 254 (21.6%) 830 (18.1%)
HIV subtype, n (%)
B subtype 203 (17.2%) 1344 (29.2%) <0.001
Non-B subtype 215 (18.3%) 316 (6.9%)
Unknown 757 (64.5%) 2938 (63.9%)
Pregnancy status at
enrolment, n (%)
51 (4.3%) 17 (0.4%) <0.001
CDC C stage at
enrolment, n (%)








317 (IQR 137–509) 396 (223–577) <0.001
First CD4 cells/mm3,
n (%)
<200 323 (27.5%) 876 (19.1%) 0.003
200–350 225 (19.1%) 732 (15.9%)
>350 440 (37.5%) 2197 (47.7%)
Missing 187 (15.9%) 793 (17.3%)
HCV coinfection, n (%)
Positive 70 (6.0%) 446 (9.7%) <0.001
Negative 792 (67.4%) 2882 (62.7%)
Unknown 313 (26.6%) 1270 (27.6%)
HBV coinfection, n (%)
Positive 58 (4.9%) 144 (3.1%) 0.008
Negative 782 (66.6%) 3060 (66.6%)
Unknown 335 (28.5%) 1394 (30.3%)
CMV coinfection, n (%)
Negative 43 (3.7%) 246 (5.3%) <0.001
Positive 492 (41.9%) 1579 (34.3%)
Unknown 640 (54.4%) 2773 (60.4%)
Sexually transmitted
diseases, n (%)
97 (8.2%) 425 (9.2%) 0.292
TABLE 1. Continued
Characteristic Migrants Natives p
Type of first regimen, n (%)
2 NRTIs + NNRTI 278 (23.7%) 1233 (26.8%) <0.001
2 NRTIs + PI boosted 502 (42.8%) 1661 (36.2%)
2 NRTIs + II 12 (1.0%) 94 (2.0%)
NRTI sparing 20 (1.7%) 97 (2.1%)
Other 30 (2.5%) 199 (4.3%)
No ART start 333 (28.3%) 1314 (28.6%)
ART, antiretroviral therapy; CDC, Centers for Disease Control and Prevention;
CMV, cytomegalovirus; HCV, hepatitis C virus; HCV, hepatitis C virus; IQR,
interquartile range; NNRTI, nonnucleoside reverse transcriptase inhibitor; NRTI,
nucleoside reverse transcriptase inhibitor.
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A total of 4126 patients (71.5%) had initiated ART at the time of
analysis, including 842 migrants (71.7%) and 3284 (71.4%)
Italian-born patients. Migrants were more likely to have
received a boosted protease inhibitor (PI)-based regimen when
beginning their ART regimen (43% of prescriptions compared
to 36% in Italian-born individuals).
At univariable analysis, migration was not associated with a
different probability of initiating ART compared to native pa-
tients (OR 1.01, 95% CI 0.87–1.17, p 0.912). However, after
adjusting for baseline characteristics at multivariable analysis,
migrant status resulted associated with a reduced frequency of
ART initiation compared to natives (OR 0.80, 95% CI 0.67–0.95,
p 0.012); the main confounder of the association between
migration and use of ART was the CD4 cell count at enrolment
(p at interaction test <0.001). The following variables were also
independently associated with a higher probability of initiating
ART by multivariable analysis: older age, higher HIV VL at
enrolment, pregnancy, occurrence of an AIDS event before
enrolment and hepatitis B virus coinfection. Self-employed sub-
jects versus full-time workers, homosexual contacts or intrave-
nous drug users versus heterosexual contacts as route of HIV
acquisition and higher CD4 count at enrolment were associated
with a lower likelihood of initiating ART (Table 2).
Response to ART
Among the 4126 subjects who initiated ART, 3167 (615
migrants and 2552 natives) were evaluable for TD and TF, and
2321 (422 migrants and 1899 natives) were subjects for VF.
After 6 months of the first ART regimen, the incidence rate of
VF was 3.3 per 100 person-years of follow-up (PYFU) (95% CI
2.8–3.9); it was higher in migrants (6.4 per 100 PYFU, 95% CI
4.8–8.5) with respect to natives (2.7 per 100 PYFU, 95% CI
2.2–3.3) (p <0.001). The TD incidence rate was 38.4 per 100
person-years (95% CI 34.4–42.8) in migrants and 30.8 in na-
tives (95% CI 29.2–32.6) (p <0.001), while the incidence rate ofious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 22, 288.e1–288.e8





pUpper Lower Upper Lower
Male gender vs. female 0.87 0.75 1.00 0.057 1.11 0.91 1.36 0.307
Age (per 10-year increase) 1.27 1.20 1.35 <0.001 1.01 1.01 1.02 0.001
Migrants vs. natives 1.01 0.87 1.17 0.912 0.80 0.67 0.95 0.012
Years from first HIV test to enrolment 0.97 0.96 0.99 <0.001 0.98 0.97 1.00 0.071
Education
Elementary school 1.00 1.00
Junior high school 0.86 0.64 1.16 0.333 1.06 0.75 1.49 0.750
High school 0.71 0.53 0.94 0.017 0.97 0.70 1.36 0.872
University 0.54 0.40 0.74 <0.001 0.85 0.59 1.23 0.396
Missing data 0.60 0.45 0.79 <0.001 0.89 0.64 1.23 0.470
Occupation
Full-time worker 1.00 1.00
Unemployed 1.00 0.83 1.20 0.978 0.90 0.72 1.12 0.341
Self-employed 0.80 0.68 0.96 0.015 0.77 0.63 0.93 0.007
Temporary employed 0.88 0.63 1.24 0.467 0.85 0.57 1.25 0.402
Housewife 1.28 0.87 1.89 0.214 0.92 0.59 1.46 0.732
Retired 1.72 1.14 2.60 0.009 0.85 0.52 1.37 0.503
Student 0.49 0.37 0.66 <0.001 0.76 0.54 1.05 0.096
Other/missing 0.71 0.61 0.82 <0.001 0.72 0.59 0.87 0.001
Mode of HIV transmission
Heterosexual contacts 1.00 1.00
Homosexual contacts 0.57 0.50 0.65 <0.001 0.77 0.65 0.91 0.002
Intravenous drug use 0.69 0.55 0.86 0.001 0.67 0.51 0.88 0.004
Other/unknown 0.74 0.59 0.93 0.010 0.78 0.60 1.01 0.058
HIV RNA, log copies/mL at enrolment
<4 1.00 1.00
4–4.999 1.49 1.28 1.73 <0.001 1.42 1.20 1.67 <0.001
5 4.44 3.67 5.37 <0.001 2.61 2.11 3.23 <0.001
Missing data 1.13 0.96 1.34 0.130 0.85 0.64 1.13 0.260
CD4 cells/mm3 at enrolment
<200 1.00 1.00
200–350 0.48 0.35 0.65 <0.001 0.68 0.49 0.94 0.020
>350 0.09 0.07 0.11 <0.001 0.13 0.10 0.17 <0.001
Missing data 0.12 0.09 0.15 <0.001 0.24 0.17 0.35 <0.001
Smoking habit
No 1.00 1.00
Yes 0.81 0.71 0.93 0.002 0.93 0.80 1.08 0.359
Unknown 0.86 0.74 1.00 0.047 0.98 0.83 1.18 0.864
Pregnancy status at enrolment 4.18 1.80 9.67 0.001 6.21 2.58 14.93 <0.001
CDC C stage at enrolment 5.07 3.65 7.04 <0.001 2.36 1.64 3.39 <0.001
HBV-Ag
Negative 1.00 1.00
Positive 1.48 1.05 2.08 0.024 1.39 0.95 2.02 0.009
Unknown 1.07 0.94 1.21 0.305 1.36 1.17 1.57 <0.001
AOR, adjusted odds ratio; ART, antiretroviral therapy; CDC, Centers for Disease Control and Prevention; CI, confidence interval; HBV-Ag, hepatitis B virus antigen; OR, odds ratio.
CMI Saracino et al. Virologic failure in migrants 288.e4TF was 44.9 per 100 person-years (95% CI 40.4–49.9) in mi-
grants and 33.2 in natives (95% CI 31.5–35.1) (p <0.001).
The multivariable models, fitted for three different out-
comes, confirmed that migrants had a significantly higher rate of
both VF (incidence rate ratio (IRR) 1.90, 95% CI 1.25–2.91, p
0.003) and TF (IRR 1.16, 95% CI 1.01–1.33, p 0.031), while no
difference was observed for the TD rate (IRR 1.09, 95% CI
0.94–1.25, p 0.248). The VF and TF cumulative probability by
means of Kaplan-Meier curves is illustrated in Fig. 1. Factors
associated with VF and TF are reported in Table 3; in particular,
in addition to the migration status, unemployment, lower CD4
count at enrolment and use of a boosted PI–based versus
nonnucleoside reverse transcriptase inhibitor (NNRTI)-based
regimen were all found to be associated with a higher proba-
bility of VF. The multivariable analysis of TF determinants
provided similar results; moreover, pregnancy status and a
tuberculosis diagnosis before ART initiation were significantly
associated with TF.Clinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and InNo association was found at univariate analysis between VF
and TF and other comorbidities including coinfections with
cytomegalovirus, viral hepatitis and sexually transmitted dis-
eases (STDs) other than HIV.
Determinants of failure in migrant patients
When considering only migrants, the variables associated with a
lower VF risk were male gender (OR 0.58, 95% CI 0.32–1.03, p
0.065) and age (for 10-year increase, OR 0.71, 95% CI
0.49–1.04, p 0.081), along with pre treatment CD4 count (per
100 cells/mm3 more, OR 0.76, 95% CI 0.60–0.96, p 0.023).
Unemployment (OR 3.08, 95% CI 1.48–6.43, p 0.003), intra-
venous drug use as risk factor for HIV acquisition (OR 2.67,
95% CI 0.94–7.55, p 0.064) and use of a boosted PI–based
regimen (OR 2.27, 95% CI 1.09–4.74, p 0.03 vs. NNRTI based)
were associated with a higher VF risk. None of these variables,
however, remained independently associated with outcome by
multivariable analysis. Regarding the patient geographical origin,fectious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 22, 288.e1–288.e8
FIG. 1. Kaplan-Meier curves representing cumulative probability of (i) virologic failure (HIV RNA >200 copies/mL) and (ii) treatment failure of first
antiretroviral regimen.
TABLE 3. Multivariable Poisson regression models of factors




ARR 95% CI p ARR 95% CI p
Male gender vs. female 0.87 0.54 1.40 0.574 0.80 0.70 0.91 0.001
Migrant vs. native 1.90 1.25 2.91 0.003 1.16 1.01 1.33 0.031
Occupation
Full-time worker 1.00 1.00
Unemployed 2.09 1.31 3.32 0.002 1.15 0.99 1.34 0.074
CD4 cells/mm3 at enrolment
<200 1.00 1.00
200–350 0.57 0.37 0.90 0.016 0.83 0.72 0.95 0.008
>350 0.57 0.35 0.93 0.024 0.93 0.81 1.07 0.317
Missing data 0.86 0.35 2.12 0.739 0.93 0.72 1.21 0.597
CDC C stage
at enrolment
2.36 1.64 3.39 <0.001 1.14 0.98 1.33 0.084
Tuberculosis
before enrolment
— — — — 1.51 1.05 2.15 0.025
Pregnancy status
at enrolment
— — — — 2.25 1.57 3.21 0.000
Type of first regimen
NRTI + NNRTI 1.00 1.00
NRTI + PI boosted 1.79 1.19 2.69 0.005 1.55 1.39 1.74 0.000
NRTI + II 1.13 0.27 4.74 0.869 0.96 0.63 1.46 0.840
NRTI sparing 2.13 0.82 5.53 0.121 1.44 1.07 1.92 0.015
Other 4.05 1.91 8.59 0.000 3.56 2.92 4.35 0.000
ARR, adjusted risk ratio; NNRTI, nonnucleoside reverse transcriptase inhibitor;
NRTI, nucleoside reverse transcriptase inhibitor; PI, protease inhibitor.
288.e5 Clinical Microbiology and Infection, Volume 22 Number 3, March 2016 CMIno differences in VF risk were evidenced. Sub-Saharan African
migrants presented a higher risk of delaying ART initiation
compared to other migrant groups at univariable analysis (OR
1.64, 95% CI 1.18–2.27, p 0.03 vs. NNRTI based); this associ-
ation, however, was not confirmed by multivariable analysis.DiscussionThe response rate to an initial ART regimen has progressively
increased in the last 10 years, approaching 90% with most
recent treatment strategies [25]. Despite this high rate ofClinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infecttherapy success in randomized clinical trials, in real life, even in
developed countries, a certain proportion of patients has been
recognized who initiate therapy late and/or have disease that
fails to respond to their first ART regimen, thus requiring a
targeted approach. In particular, our study demonstrates that
migrants still represent a vulnerable subgroup in terms of ac-
cess to ART and of failure risk, despite the availability in Eu-
ropean countries of an universal health care system which
assures equal access to highly active ART and health care fa-
cilities for all HIV-infected patients and which, in Italy, is also
extended to undocumented individuals.
Similar to previous studies, in the present analysis, migrants
were diagnosed with HIV infection later compared to natives
[1,2,4–7], thereby confirming the need to increase HIV testing
in the most vulnerable migrant and ethnic minority populations.
This result recalls the debate concerning the necessity to
establish a mandatory HIV test when entering Europe, which is
not accepted in many countries, including Italy [26], in order to
avoid discriminatory practices. In univariate analysis, migrants
were found to initiate ART as frequently as natives; however,
migrants had lower CD4 cell counts at baseline, and after
adjusting for the baseline CD4 level, they showed a lower
probability to initiate ART compared to native patients. This
finding confirms previous observations [10–27] although it is
partially in disagreement with the survey of Jarrin et al. [18]
regarding a cohort of seroconverted patients in Europe, Can-
ada and Australia (CASCADE) in which no association between
geographical origin and ART uptake was found in settings with
universal access to healthcare. Differences in the population
studied (i.e. seroconverters versus new and prevalent cases)
may at least partly explain the disparity between studies.
Moreover, Italy is often considered a transit country for un-
documented immigrants from across the Mediterranean who
generally seek their destination countries later. Therefore, thisious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 22, 288.e1–288.e8
CMI Saracino et al. Virologic failure in migrants 288.e6high migrant mobility in our country might induce both patients
and clinicians to delay initiation of ART in patients with a
relatively high CD4 level at presentation.
Migrants experienced ART failure more frequently than na-
tives. This finding was consistent in our analysis independent of
the method used to define failure, as higher rates of VF, TD and
TF were observed for this patient population. In particular, the
risk of VF of >200 copies/mL in migrants was nearly twice that of
natives (6.4 vs. 2.7 per 100 person-years). Different rates and
predictors of VF according to race and ethnicity have been
previously described; however, data regarding response to ART
in migrants are controversial in the literature [12–19]. In most
studies, similar disease progression and mortality or even better
survival has been found for migrants compared to natives,
although possible confounders are very difficult to eliminate,
such as the health migrant effect (only healthy people embark on
a migratory project) and the salmon bias (caused by sick people
returning home to die) can lead to erroneous conclusions [28].
A few studies specifically analysed response to therapy, and in
particular to the first ART regimen [17,29,30]. Among these, the
Spanish study of Pérez Molina et al. [17], even if concluding that
response to ART among immigrants was similar to that of
autochthonous individuals, found a shorter time to TF in the
subgroup of Sub-Saharan African and female migrants.
Why migration should determine a higher risk of VF remains
unclear. It could be supposed that migrants are less adherent to
therapy than natives, even if neither direct measurement of
adherence levels was available in this study or evidence of such
a difference is proven in the literature. In our study, the reasons
underlining failure appeared to be linked more to VF rather
than to treatment discontinuation, which was not indepen-
dently associated with migration by multivariable analysis, thus
excluding the notion that different tolerability profiles and side
effects might have influenced ART response.
The epidemiology of other concomitant infections and
comorbidities was very different in the two groups at baseline
but was not associated with VF. Among opportunistic in-
fections, however, tuberculosis was associated with TF with
multivariable analysis, as has also been suggested by others [12];
aspects related to drug interactions could play a crucial role in
this context. However, the prevalence of other STDs was
similar in natives and migrants. In fact, Europe is facing a general
epidemic-level increase in all STDs, and public health campaigns
would be suitable to address this issue [1].
Other viral characteristics (HIV-1 subtype, tropism, trans-
mitted drug resistance [20,21]) and host genetic factors (HLA
B5701 frequency [22]) should also be taken into account; these
data, however, were not available for our analysis. Regarding
behavioural and socioeconomic issues, younger age and unem-
ployment were found to be associated with VF in the migrantClinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Insubgroup, thus suggesting that as a result of overwhelming
occupational problems HIV care would not be a priority for all
migrants. Other sociocultural aspects not directly investigated
here (i.e. the role of stigma in some settings or the presence of
linguistic barriers) might have determined a lesser willingness to
receive treatment or increased risk of failure. Moreover, it
should be acknowledged that it is always difficult to group all
migrants in an unique category when analysing data (and this also
presents a limitation of our study) as a result of the high het-
erogeneity which characterizes people of different origins.
With respect to treatment strategies, the use of boosted PIs
was associated with poorer outcomes. The concept that mi-
grants might require a high-genetic-barrier regimen because of
a supposed lack of adherence has probably induced Italian cli-
nicians to prescribe a PI-based regimen more frequently than
NNRTIs for migrants compared to natives. Our study suggests
a need to promote adherence using a simpler regimen. How-
ever, as a consequence of implementing World Health Orga-
nization programs regarding introduction of highly active ART
in developing countries, based up to now mainly on nevirapine
and efavirenz as first-line therapy, the risk of primary resistance
to NNRTIs in African patients might increase [21]; this should
be evaluated by clinicians before selecting the first regimen.
In conclusion, despite the use of more potent and safer an-
tiretroviral drugs in the last 10 years, and even in a setting of
universal access to ART, migrants living with HIV still present
barriers to ART initiation and an increased risk of VF compared
to natives. Therefore, they require strict and careful manage-
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